Ginkgo Bioworks shares surge 19.77% intraday after AI-driven lab slashes protein synthesis costs by 40%.

Ginkgo Bioworks (NYSE: DNA) surged 19.77% during intraday trading following the announcement of a collaboration with OpenAI to deploy a GPT-5-driven autonomous laboratory. The system autonomously designed, executed, and learned from 36,000 experiments, achieving a 40% cost reduction in cell-free protein synthesis while generating nearly 150,000 data points. The commercialization of the AI-optimized reaction mix through its reagents store highlights the platform’s immediate economic potential. The study, validated by rigorous experimental design and open-source tools, underscores Ginkgo’s transition from synthetic biology services to an AI-native science infrastructure, aligning with U.S. government initiatives to advance AI-driven research. This breakthrough positions the company as a scalable player in biology optimization, directly linking the stock’s sharp rise to demonstrated technological and commercial progress.